Egyptian Exchange leads COMESA in attracting foreign investments    NBE: Exchange rates of key global currencies rates Tuesday 24-11-2020 vs. Egyptian pound    Orascom-Mitsubishi consortium signs $800m contract for Cairo Metro Line 4    UN alarmed at military build-up around Tigray capital    Japan can host Olympics despite virus spike: Tokyo governor    Eight positive in latest Premier League COVID-19 tests    Russia caught US warship in its waters, chased it off: defence ministry    President El-Sisi visits Madkour's pavilion at the International Intelligent Transport Exhibition and listens to an explanation from,Dr. Mostafa Madkour about the company's activities    Biden transition gets govt OK after Trump out of options    Egypt detects 354 new coronavirus cases, 12 deaths on Monday    Sisi, telecom company Orange discuss increasing cooperation in Egypt    Cairo International Book Fair suspended for five months over coronavirus concerns    Suspension of CAF boss Ahmad opens elections race wide open    AstraZeneca novel COVID-19 vaccine can be 90% effective, results show    Egypt's military production minister, S. Korean ambassador discuss boosting industrial cooperation    Polling stations open at home for 1st stage of Egyptian parliamentary run-offs    Liverpool coach Klopp blasts broadcasters over hectic match schedule    Egypt detects 351 new coronavirus cases, 13 deaths on Sunday    Winners of the 5th Sharm El-Sheikh Int'l Theatre Festival for Youth    Egypt confirms 358 new coronavirus cases, 14 deaths on Saturday    BREAKING: Sudan decides not to participate in ministerial meeting on GERD Saturday    G20 to discuss post-pandemic world, back debt relief    First day of Egypt's parliamentary runoffs kicks off for expats    US will reduce number of its troop in Iraq, Afghanistan    Don't miss the concerts of the 12th Cairo International Jazz Festival    Asia forms world's biggest trade bloc, a China-backed group excluding U.S    Egypt unveils largest archaeological discovery in 2020 with over 100 intact sarcophagi    Palestinians mourn the loss their longtime spokesman, Saeb Erekat    Egypt, Ethiopia, Sudan to resume Nile dam talks today    Trump says won't blame Egypt for being ‘upset' over GERD dispute with Ethiopia    1st stage of Egypt's parliamentary elections kicks off on Saturday    Global Finance: Egypt's Tarek Amer among the world's top 20 central bank governors    Legend footballer Lionel Messi says he is forced to stay with Barcelona    Iraqi conglomerate eyes developing land that housed Mubarak-era ruling party HQ    Famous Egyptian actor Mahmoud Yassin passes away at 79    Legend Messi officially wants to leave Barcelona, hands transfer request    The Facebook Preacher's Search for Fame, and Egypt's Economy    Egypt calls on UNSC to address oil spill risks off Yemen coast    Egypt economically strong in face of COVID-19, reforms ongoing: International Cooperation Minister    Arafa Holding reports $144,000 COVID-19-related losses in April    Egypt's efforts in Libya to activate free will of Libyan people: Al-Sisi    Hyksos campaigns were internal takeover, not foreign invaders: study    COVID-19 affects Egypt sporting clubs    COVID-19 will soon turn to seasonal like swine flu: Presidential Health Advisor    ‘Egypt's Support' coalition convenes to discuss its Senate election list    Robbery attempt leads to discovery of Ptolemaic monuments in Qena    Flouting international guidance, Ethiopia unilaterally starts filling its Nile dam    Zaha speaks out after online racial abuse    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.





Sanofi eyes approval of COVID-19 vaccine by first half of 2021
Published in Ahram Online on 23 - 06 - 2020

French drugmaker Sanofi SA said on Tuesday it expects to get approval for the potential COVID-19 vaccine it is developing with Britain's GlaxoSmithKline Plc by the first half of next year, faster than previously anticipated.
Sanofi, which is hosting a virtual research and development event, and GSK had said in April the vaccine, if successful, would be available in the second half of 2021.
"We are being guided by our dialogue with regulatory authorities," Sanofi research chief John Reed told reporters, when asked about the accelerated time frame.
There are currently no vaccines to prevent the coronavirus that has infected more than 9 million people and killed over 469,000 globally, and only a couple of medicines that have demonstrated benefit in hospitalized COVID-19 patients in clinical trials.
Many drugmakers are racing to come up with a safe and effective vaccine that can be produced at large scale.
Moderna Inc, the University of Oxford in collaboration with AstraZeneca Plc, and an alliance of BioNTech and Pfizer Inc grabbed headlines by moving to human trials as early as March.
Sanofi Chief Executive Paul Hudson said the firsts in the race now were not assured of securing victory.
"There are companies moving faster, but let us be brutally clear, speed has three downsides," he said of competition.
"They are using existing work, in many cases done for SARS; it is likely not to be as efficacious; and there is no guarantee on supply in large volumes," Hudson said.
The probability of success for Sanofi is "higher than anybody else," the CEO said.
The comments echoed those of GSK, whose chief medical officer for vaccines told Reuters on Friday the company was aiming at quality before speed.
Sanofi, whose Pasteur vaccines division has a long established reputation, notably in flu, is currently working on two vaccine projects.
One uses an adjuvant made by GSK to potentially boost its efficacy. It has received financial support from the U.S. Biomedical Advanced Research and Development Authority (BARDA).
The other, being developed with U.S. company Translate Bio Inc, relies on a different technology known as mRNA, similar to the Moderna approach.
Clinical trials of the vaccine developed with GSK, described as a recombinant vaccine because of the use of GSK's boosting adjuvant, are to start in September. Trials of the mRNA vaccine candidate should begin around the end of the year, the company said.
Sanofi said it had capacity to produce up to 1 billion doses a year of its recombinant vaccine, and that it would be able to supply up to 360 million doses of its mRNA vaccine annually.
In April, Sanofi said it had manufacturing capacity for 600 million doses for its recombinant vaccine, with the ambition to double production by mid-2021.
The company also said it would expand its collaboration with Translate Bio on developing vaccines, in a deal which will give the U.S. group $425 million in upfront payments.


Clic here to read the story from its source.